Year: 2026

Introducing the first exchange-cleared benchmark to hedge solar output variability in Europe’s largest power market TORONTO, April 23, 2026 (GLOBE NEWSWIRE) — Abaxx Technologies Inc. (CBOE:ABXX)(OTCQX:ABXXF) (“Abaxx” or the “Company”), a financial software and market infrastructure company, indirect majority shareholder of Abaxx Singapore Pte Ltd. (“Abaxx Singapore”), the owner of Abaxx Commodity Exchange and Clearinghouse (individually, “Abaxx Exchange” and “Abaxx Clearing”), today announced that trading has commenced in Enwex Germany Solar (GSM) futures, extending its suite of weather-indexed benchmarks to include solar exposure in Europe’s largest power market. As solar capacity continues to scale across Germany, variability in irradiance is becoming a more material driver of realized output and revenue variability for market...

Independent material testing shows battery-grade graphitization level of over 96% MONTREAL, April 23, 2026 (GLOBE NEWSWIRE) — PyroGenesis Inc. (“PyroGenesis” or “the Company”) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), a leader in ultra-high temperature processes and engineering innovation, and a plasma-based technology provider to heavy industry & defense, announces, further to its press release dated April 21, 2026, the successful production of high quality battery-grade graphite from carbon black, using a proprietary plasma process. Of note, the carbon black used to produce the graphite was itself produced by PyroGenesis in a first-ever achievement where both a natural gas-powered and a methane-powered plasma torch acted as the sole feedstock (i.e. the gas flowing through the torch to create plasma acts as the feedstock that...

PARIS and AMSTERDAM and FORT COLLINS, Colo., April 23, 2026 (GLOBE NEWSWIRE) — Air France Industries KLM Engineering & Maintenance (AFI KLM E&M) has signed an Elite Licensed Repair Service Facility (LRSF) Agreement with Woodward to support the CFM International LEAP-1A and LEAP-1B* engines. Under this agreement, AFI KLM E&M is now authorized to deliver a full suite of maintenance, repair, and overhaul (MRO) services for Woodward components across the CFM LEAP engine family. This includes fuel controls, actuators, pumps, and valves—critical systems ensuring optimal engine performance and reliability. With a rapidly expanding global CFM LEAP engine fleet, this agreement strengthens AFI KLM E&M’s position as a CFM Premier MRO Provider, making it a key player in next-generation engine support. It also reinforces...

Genenta enters aerospace as it continues its strategic transformation into a next-generation industrial consolidator MILAN,Italy, April 23, 2026 (GLOBE NEWSWIRE) — Genenta Science S.p.A. (Nasdaq: GNTA), evolving into Saentra Forge1, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian national-security-related technologies, today announced that it has signed definitive agreements2 with Sòphia High Tech S.r.l., (Sòphia HT) an Italian company manufacturing critical parts for Europe’s space and defense programs. Genenta expects to fund a total of €6.0 million in two tranches. With the closing of the first tranche, Genenta will obtain a 19.9% stake, and with the closing of the second tranche, Genenta will own a 51% stake in Sòphia HT. The proceeds are expected to be deployed by Sòphia HT to materially...

Completed enrolment in Phase 2b clinical trial of imaging agent RAD 101 in patients with recurrent brain metastases following earlier announcement of interim data demonstrating concordance with MRI (the primary endpoint) in 90% of evaluable subjects (18/20) Presented initial Phase 0/1 data for RAD 202 at the American Association for Cancer Research demonstrating encouraging tumor uptake and a favorable safety profile in the lowest dose cohort Received positive recommendation from Data and Safety Monitoring Committee (DSMC) to advance RAD 202 to the next dose level Initiated two First-In-Human (FIH) clinical trials for radiotherapeutic assets RV-01 in various tumor types and RAD 402 in advanced prostate cancer SYDNEY, April 23, 2026 (GLOBE NEWSWIRE) — Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”),...

SAN FRANCISCO and VANCOUVER, British Columbia, April 23, 2026 (GLOBE NEWSWIRE) — Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that Jade’s Board of Directors granted an equity award to Edward R. Conner, M.D., effective as of April 22, 2026, in connection with his appointment as Chief Medical Officer. The Board of Directors granted Dr. Conner non-qualified stock options to purchase an aggregate of 500,000 shares of the Company’s common stock under the Jade Biosciences, Inc. Employment Inducement Stock Incentive Plan (the “Inducement Plan”). The option grant was granted as an inducement material to Dr. Conner entering into employment with Jade in accordance with Nasdaq Listing Rule 5635(c)(4). The...

AB Artea bankas (ROE1L) invites shareholders, investors, analysts and other stakeholders to join its Investors Webinar on the Q1 2026 financial results and highlights. The webinar will take place on 28 April 2026 at 8:30 a.m. (EEST) and will be held online in English. The webinar will be hosted by Vytautas Sinius, CEO, Tomas Varenbergas, CFO and Tautvydas Mėdžius, Strategy Partner, who will discuss the bank’s financial results for Q1 2026, recent developments, and will take questions from participants. Participants are encouraged to submit questions in advance to investors@artea.lt. The Q1 2026 results will be announced in advance on 27 April after trading hours. How to join the webinar: To join the webinar, please register via following link https://artea.zoomtv.lt. After successful registration You will be provided with the webinar link....

PRINCETON, N.J. and SUZHOU, China, April 23, 2026 (GLOBE NEWSWIRE) — Transcenta Therapeutics (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, today announced the presentation of preclinical data highlighting its proprietary LIV1-targeting antibody-drug conjugates (ADC) at the 2026 AACR Annual Meeting. The data demonstrate strong anti-tumor activity, differentiated payload-dependent efficacy, and favorable tolerability profiles, supporting further development in LIV1-positive solid tumors. LIV1 is a member of the zinc transporter family, with limited normal tissue expression, and is found to be overexpressed with high prevalence in breast (93%), prostate (72%) and lung (10%) cancers, making it an...

Dosing initiates clinical evaluation of NPX-5, a GMP-compliant, nature-derived psilocybin candidate across an expanded Australian site network NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a clinical-stage biopharmaceutical company developing nature-derived psychedelic therapeutics, today announced that the first patient has been dosed in its Phase IIb clinical trial evaluating NPX-5 (25mg of nature-derived psilocybin) for the treatment of Adjustment Disorder in patients with cancer in a palliative care setting. The initiation of dosing represents the first active clinical evaluation of NPX-5 at scale and marks the Company’s transition into systematic human data generation across its Australian clinical network. NPX-5 is a GMP-compliant, nature-derived psilocybin...